Abstract: Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.
Abstract: The present invention provides a non-surgical method for treating prolapsed hemorrhoids. The first step is to clean the anus and surrounding areas, preferably with soap and warm water. The second step is to apply a powder that increases friction and dries the surface of the hemorrhoid. The third step is to gently push the prolapsed hemorrhoid back through the anal sphincter. After reinsertion, the drying effect of the powder prevents the hemorrhoid from prolapsing again by sufficiently increasing the friction to prevent passage through the anus. Held internally, the hemorrhoid shrinks, increasing user comfort.
Abstract: A method of treating a JAK-inhibition-responsive condition (such as a hair loss disorder) in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of Compound (I) or a pharmaceutically acceptable salt thereof, wherein each position designated specifically as deuterium has at least 95% incorporation of deuterium; and wherein: the subject is receiving a concomitant administration of a CYP3A4 inhibitor; and the therapeutically effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, is not reduced compared to the therapeutically effective amount of Compound (I), or pharmaceutically acceptable salt thereof, that would be administered to the subject in the absence of concomitant administration of a CYP3A4 inhibitor.
Type:
Grant
Filed:
October 20, 2023
Date of Patent:
April 29, 2025
Assignee:
Sun Pharmaceutical Industries, Inc.
Inventors:
James V. Cassella, Christopher L. Brummel
Abstract: A pharmaceutical composition for topical wound treatment comprising one or more nitrogenous heterocyclic compound of 5 or 6 atoms with imide group; one or more deoxyribonuclease enzyme with activity pH between 4.5 and 6.5; and one or more carboxylic acid; kits and process to obtain this pharmaceutical composition and uses for wounds treatment.
Type:
Grant
Filed:
April 5, 2022
Date of Patent:
April 22, 2025
Assignees:
CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS, UNIVERSIDAD NACIONAL DE TUCUMAN, UNTECH INC.
Inventors:
Alberto Ramos Vernieri, Maria De Los Angeles Lazarte, Romina Mabel Chavez Jara, Nicolas Abel Cerusico
Abstract: A composition comprising an active agent that inhibits acyl-coenzyme A:cholesterol acyltransferase (ACAT) is provided. With the composition, food intake can be suppressed, and/or body weight can be reduced, and/or metabolic disorders can be prevented and/or treated.
Abstract: A composition comprising an active agent that inhibits acyl-coenzyme A:cholesterol acyltransferase (ACAT) is provided. With the composition, food intake can be suppressed, and/or body weight can be reduced, and/or metabolic disorders can be prevented and/or treated.
Abstract: The invention relates to the treatment of ascites, and especially refractory ascites, with an orally bioavailable prodrug of dopamine. A preferred prodrug of dopamine is docarpamine. The invention preferably contemplates intermittent dosing, wherein a treatment period is followed by an off-treatment period, which is followed by another treatment period.
Abstract: There is disclosed an oral pharmaceutical formulation of bitter compounds that are agonists of TAS2R receptors for the treatment of pulmonary hypertension (PAH). More specifically, there is disclosed a PAH oral formulation comprising a bitter agent selected from the group consisting of 3-caffeoylquinic-1,5-lactone (3-CQL), chlorogenic acid (CGA), denatonium benzoate (DB), denatonium chloride (DC), denatonium saccharide (DS), denatonium acetate (DA), and combinations thereof and a PDE-5 inhibitor.
Abstract: Disclosed are methods of treating a subject having a disease or disorder by administering a monoamine oxidase inhibitor in combination with a serotonin receptor agonist, which in some embodiments is a deuterated serotonin receptor agonist. In some aspects, the disclosure further relates to pharmaceutical compositions and kits comprising a monoamine oxidase inhibitor and a serotonin receptor agonist. In some embodiments, the monoamine oxidase inhibitor is a MAO-A-selective inhibitor such as CX157, and the serotonin receptor agonist is a serotonin 2A receptor agonist such as N,N-dimethyltryptamine (DMT), or deuterated DMT.
Type:
Grant
Filed:
March 25, 2024
Date of Patent:
April 1, 2025
Assignee:
Remedi, Inc.
Inventors:
Tom Spector, Jeremy Ford, Thomas A. Krenitsky
Abstract: A composition comprising an active agent that inhibits acyl-coenzyme A:cholesterol acyltransferase (ACAT) is provided. With the composition, food intake can be suppressed, and/or body weight can be reduced, and/or metabolic disorders can be prevented and/or treated.
Abstract: This invention relates to a dilute, ready-to-use solution of phenylephrine hydrochloride having improved stability and utility. In a particular embodiment, the formulation consists of an injectable form of phenylephrine hydrochloride with edetate disodium chelating agent in place of any sodium metabisulfite antioxidants to improve the solution's ability to remain stable and active in a dilute state after prolonged storage. This invention also relates to a form for injection of the solution that includes packaging the solution in a single-use container, as well as a form for containing the ready-to-use solution in a sterile, sealed container. Lastly this invention relates to methods of making the injectable solution for use in a single-use container, as well as for containment in a sterile, sealed container.
Type:
Grant
Filed:
September 9, 2022
Date of Patent:
March 25, 2025
Assignee:
Hikma Pharmaceuticals USA Inc.
Inventors:
David E. McAnany, Michael G. Parker, Sarah D. Mccue
Abstract: A use of a FAK inhibitor in the preparation of a drug for preventing and/or treating tumors having an NRAS mutation. A method for treating tumors that have experienced an NRAS mutation, which comprises administering an effective dose of a FAK inhibitor to an individual. A FAK inhibitor for treating tumors having an NRAS mutation. The FAK inhibitor is B1853520, defactinib, GSK2256098, PF-00562271, VS-4718 or a pharmaceutically acceptable salt thereof.
Abstract: A sesquiterpenoid derivative and use thereof in preparing a broad-spectrum antiviral drug provided. The sesquiterpenoid derivative can stimulate heterogeneous nuclear ribonucleoprotein A2/B1, activate the cell signal pathway of TANK-binding kinase 1-interferon regulatory factor 3, and increase the expression and secretion of endogenous type I interferon. As a result, it can inhibiting various viruses and can be used as a broad-spectrum antiviral drug for preventing or treating various viral infectious diseases and symptoms, including Covid-19, vesicular stomatitis virus VSV-G, AIDS virus, hepatitis C virus, Japanese encephalitis virus, influenza virus, poliovirus, Coxsackie virus, dengue virus, rotavirus, tobacco mosaic virus, measles virus, mumps virus, Ebola virus, Marburg virus, herpes virus and adenovirus.
Type:
Grant
Filed:
April 2, 2024
Date of Patent:
March 25, 2025
Assignee:
KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY
Abstract: The present invention relates to stable, aqueous, parenteral solutions comprising diclofenac and polyvinylpyrrolidone, wherein the solutions are for parenteral (subcutaneous, intravenous and/or intramuscular) administration to a mammal.
Abstract: Embodiments of the instant disclosure relate to novel methods and compositions for treating tumors resistant to one or more anticancer drugs, such as platinum-based chemotherapeutics.
Abstract: This discloses that compounds of Formula 1 may be used as antifibrotics because they inhibit type 1 collagen production. In particular, this discloses a pharmaceutical composition containing one or more compounds of Formula 1 and methods of using compounds of Formula 1 in fibrosis treatment and inhibiting type 1 collagen synthesis.
Type:
Grant
Filed:
November 22, 2022
Date of Patent:
March 25, 2025
Assignee:
Florida State University Research Foundation, Inc.
Abstract: The disclosure relates polyoxometalate complexes and uses in the management, treatment, or prevention of cancer. In certain embodiments, the polyoxometalate complexes comprise polydentate oxygen bridging ligands such as those of the following formula: [POM{(OCH2)3CX}2], [M6O13{(OCH2)3CX}2], [V6O13{(OCH2)3CX}2], salts, or derivatives thereof wherein POM is a polyoxometalate, M is a metal, and X is defined herein. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising polyoxometalate complexes disclosed herein.
Abstract: This disclosure relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a baseline NIHSS of ?20. In other embodiments, patients have lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo treatment with a thrombolytic agent and/or decompressive therapy.
Type:
Grant
Filed:
June 5, 2024
Date of Patent:
March 18, 2025
Assignee:
REMEDY PHARMACEUTICALS, INC.
Inventors:
Sven Martin Jacobson, Thomas W. Macallister
Abstract: Provided are methods of preventing, delaying, mitigating, reducing and/or inhibiting alpha-synuclein aggregates in the brains of a subject at risk of developing or suffering a cognitive disease associated with, caused and/or mediated at least in part by alpha-synuclein aggregates, for example, Parkinson's Disease or Dementia with Lewy Bodies (DLB).
Type:
Grant
Filed:
February 5, 2019
Date of Patent:
March 18, 2025
Assignees:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, CHIBA UNIVERSITY
Inventors:
Bruce D. Hammock, Sung Hee Hwang, Kenji Hashimoto, Qian Ren
Abstract: Provided herein are antileishmanial compounds, compositions comprising the antileishmanial compounds, and use thereof.
Type:
Grant
Filed:
May 25, 2023
Date of Patent:
March 18, 2025
Assignees:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, FUNDAÇÄO OSWALDO CRUZ
Inventors:
Scott E. Schaus, Lauren E. Brown, Mark W. Grinstaff, Danielle M. Fitzgerald, Diana L Diaz, John A. Kavouris, Jair Lage De Siqueira-Neto, James McKerrow, Camila Indiani De Oliveira